Search NLS News

A new study from Karolinska Institutet shows how certain RNA molecules control the repair of damaged DNA in cancer cells, a discovery that could eventually give rise to better cancer treatments. New research demonstrates that RNA molecules have a much broader function than previously thought and can play a key role in the development of […]

The Russian invasion of Ukraine will affect the lives of millions of people, and it also presents a danger to scientific work in the country. In a recent article in Nature, 19 February 2022, several Ukrainian researchers say that the conflict with Russia will hinder progress made since Ukraine’s revolution in 2014. “In general, this […]

Cantargia has reported new encouraging results from non-GLP toxicology and pharmacokinetic studies for its anti-inflammatory IL1RAP-binding antibody CAN10. Results show no toxicologically relevant changes using a new subcutaneous formulation, with high bioavailability and desirable pharmacological half-life, states the company. Further studies using intravenous administration show good safety by repeated dosing at 50 mg/kg. The GLP […]

Spago Nanomedical has received approval from the Swedish Medical Products Agency to initiate recruitment of patients with pancreatic cancer for the clinical study with the contrast agent SN132D. ”By including another patient group, we can in a cost-effective way demonstrate a broader use of SN132D and build additional value in the SpagoPix project at an […]

Targovax has entered into a two-year research collaboration with Professor Michael Uhlin of the Department of Clinical Science, Intervention and Technology at Karolinska Institutet, to develop and characterize novel ONCOS oncolytic viruses. “Prof. Uhlin is a highly accomplished scientist with deep experience in translational and clinical immunology. His expertise and research capabilities will play a […]

Alexion, AstraZeneca’s Rare Disease group, has closed an exclusive global collaboration and licence agreement with Neurimmune AG for NI006. NI006 is an investigational human monoclonal antibody currently in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), an underdiagnosed, systemic condition that leads to progressive heart failure and high rate of fatality within […]

A functional precision medicine study conducted in Finland demonstrates that treatment selection based on results from drug sensitivity testing of patients’ cells can be clinically useful in patients with aggressive hematological cancers. Clinicians, researchers and technology experts from the Institute for Molecular Medicine Finland FIMM at the University of Helsinki and Helsinki University Hospital Comprehensive […]

The company has announced the appointment of Christophe Bourdon as new Chief Executive Officer, effective April 1, 2022. Christophe Bourdon joins from Orphazyme A/S where he has held the position as CEO since April 2021, following global leadership roles in both Amgen and Alexion. Read more: LEO Pharma introduces a new operating model and organizational […]

The U.S. Food and Drug Administration has granted the designation for the company’s vaccine candidate for active immunization for prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults aged 60 years or older. The designation has been granted upon the assessment of preliminary clinical evidence for the vaccine candidate, MVA-BN […]

The Center for Drug Evaluation (CDE) has recommended approval of Gamifant to the National Medical Products Administration of China (NMPA). The indication is for treatment of adult and paediatric (newborn and older) patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy. “We are gratified that CDE […]